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Abstract
Background:  The nucleotide excision repair (NER) protein, xeroderma pigmentosum C (XPC), participates in
recognizing DNA lesions and initiating DNA repair in response to DNA damage. Because mutations in XPC cause a high
risk of cancer in XP patients, we hypothesized that inherited sequence variations in XPC may alter DNA repair and thus
susceptibility to cancer.
Methods:  In this hospital-based case-control study, we investigated five XPC  tagging, common single nucleotide
polymorphisms (tagging SNPs) in 1,010 patients with newly diagnosed lung cancer and 1,011 matched cancer free
controls in a Chinese population.
Results: In individual tagging SNP analysis, we found that rs3731055AG+AA variant genotypes were associated with a
significantly decreased risk of lung adenocarcinoma [adjusted odds ratio (OR), 0.71; 95% confidence interval (CI), 0.56–
0.90] but an increased risk of small cell carcinomas [adjusted OR, 1.79; 95% CI, 1.05–3.07]. Furthermore, we found that
haplotype ACCCA was associated with a decreased risk of lung adenocarcinoma [OR, 0.78; 95% CI, 0.62–0.97] but an
increased risk of small cell carcinomas [OR, 1.68; 95% CI, 1.04–2.71], which reflected the presence of rs3731055A allele
in this haplotype. Further stratified analysis revealed that the protective effect of rs3731055AG+AA on risk of lung
adenocarcinoma was more evident among young subjects (age ≤ 60) and never smokers.
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Conclusion: These results suggest that inherited sequence variations in XPC may modulate risk of lung cancer, especially
lung adenocarcinoma, in Chinese populations. However, these findings need to be verified in larger confirmatory studies
with more comprehensively selected tagging SNPs.
Background
The high incidence of lung cancer is a major public health
problem worldwide [1]. In China, lung cancer has
become the leading cause of cancer-related deaths in both
men and women [2]. A number of epidemiological stud-
ies have confirmed that approximate 90% of individuals
with lung cancer had a direct exposure to tobacco smoke
[3], in which some carcinogens can result in DNA dam-
age, leading to genomic instability and malignant trans-
formation of the cell [4]. Nevertheless, only a small
fraction of smokers develops lung cancer, suggesting that
individual susceptibility may play an important role in
the etiology of lung cancer [5].
Lung cancer risk is likely due to an interplay between
exposure to etiologic agents and cellular stress response
[6]. Under normal conditions, the levels of DNA damage
and the capacity of DNA repair systems maintain a
dynamic balance; and deficient repair systems can result
in either altered apoptosis or unregulated cell growth that
leads to carcinogenesis[7]. In humans, DNA damage
caused by either ultraviolet light in the sun and carcino-
gens in cigarette smoke is mainly repaired by the nucle-
otide excision repair (NER) pathway [8-10]. Considerable
evidence suggests that NER capacity is crucial in maintain-
ing normal cell functions, and variations the in DNA
repair capacity (DRC) among individuals may contribute
to differences in risk of cancers, including lung cancer
[11]. The underlying molecular mechanisms of individual
variation in cancer susceptibility are thought to be due to
genetic polymorphisms, particularly single nucleotide
polymorphisms (SNPs) involved in cellular mechanisms,
such as DNA repair, that maintain normal cell growth
[12]. Therefore, it is likely that inherited sequence varia-
tions of the NER genes mayaffect individual susceptibility
to cancer as seen in the recessive genetic syndrome xero-
derma pigmentosum (XP) [13].
Recently, two studies in Asian populations [14,15] suggest
that genetic polymorphisms in the XPC gene may be asso-
ciated with risk of lung cancer, but these studies were
either relatively small or the genotyping work did not take
into account of all reported SNPs in the XPC gene. To fur-
ther investigate the association between the XPC gene and
risk of lung cancer in Chinese populations, we took a dif-
ferent approach. Using the XPC SNP information availa-
ble in the National Institute of Environmental Health
Sciences (NIEHS) Environmental Genome Project (EGP)
SNP database, we identified five representative tagging
SNPs that may capture all 29 common (i.e., a minor allele
frequency, MAF, ≥ 0.1) SNPs out of 145 reported SNPs
[16]. Then, we conducted a large-scale case-control study
with 1,010 primary lung cancer patients and 1,011 age
and sex frequency-matched cancer-free controls in a Chi-
nese population to evaluate the association between XPC
genotypes/haplotypes containing variant alleles of these
selected tagging SNPs and lung cancer risk.
Methods
Study subject
The subject recruitment was described elsewhere [17].
Briefly, all the subject were genetically unrelated ethnic
Han Chinese; all patients with primary lung cancer diag-
nosed between July 2002 and November 2004 according
to the National Diagnosis Standard for Lung Cancer were
consecutively recruited from four hospitals of three met-
ropolitan cities along the Yangzi River, including the Can-
cer Hospital of Jiangsu Province, the First Affiliated
Hospital of Nanjing Medical University, the Shanghai
Cancer Hospital of Fudan University, and the Wuhan
Zhongnan Hospital. There were no age, sex, and histology
restrictions, but the patients with previous cancer history
or unknown conditions of radiotherapy or chemotherapy
were excluded. During the study period, a total of 1,299
patients who had confirmed lung cancer by histopatho-
logic diagnosis were recruited from these hospitals, of
these patients 1,010 signed inform consents to participate
in this study and provided blood samples, resulting in a
response rate of 77.8% (1,010/1,299). The cancer-free
control subjects came from other clinics departments of
the same hospitals during the same period when the cases
were recruited. They were outpatients in the clinics of gen-
eral surgery, gynecology, internal medicine, orthopedics,
and otorhinolaryngology and without any tobacco-
related diseases, such as emphysema and bronchitis, in
the lung. All controls were frequency matched to the cases
by age (± 5 years), sex, and residential area (urban or
countryside). The response rate in the eligible controls,
who signed the informed consent form and donated
blood samples, was 81.3% (1,011/1,244).
Epidemiologic data were collected by trained interviewers
through a structured questionnaire, which elicited infor-
mation about sociodemographic characteristics, recent
and prior tobacco smoke history, passive smoking, and
personal and family history of cancer defined as any
reported cancer in the first-degree relatives. Participants
who smoked less than one cigarette per day in shorterBMC Cancer 2007, 7:81 http://www.biomedcentral.com/1471-2407/7/81
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than one year were defined as nonsmokers; otherwise,
they were considered smokers. The smokers' cumulative
smoking dose (pack-years) was defined as the number of
packs of cigarettes smoked per day multiplied by the
number of smoking years. The cut-off point to classify
light and heavy smokers was based on the median pack-
years of the smokers in the controls. After interview,
approximate 5-ml venous blood sample was collected
from each participant. The institutional review boards of
Nanjing Medical University, Fudan University, and Tongji
Medical College of Huazhong University of Science and
Technology approved the study protocols.
Polymorphism selection
The tagging SNPs were selected from the resequencing
data of 90 individuals with mixed ethnic background in
the NIEHS EGP SNP database [18], base on the following
criteria: a) a MAF of at least 0.05 or greater in the promoter
region and 0.10 or greater across the whole genomic
region, b) putative functional potentials SNPs (i.e., non-
synonymous SNPs, promoter SNPs, and SNP at exon-
intron boundaries), and c) SNPs that were in linkage dis-
equilibrium (LD) with other SNPs (the threshold of min-
imal pair-wise r2 = 0.4 due to financial constraints). Based
on the first criteria, there were 29 common SNPs in the
145 reported SNPs in the XPC gene. We selected the tag-
ging SNPs based on the MAFs of a mixed ethnic group
included in the NIEHS EGP SNP database at the time
when the HapMap data were not available, in which the
MAFs of some SNPs of interest from a subset of Chinese
are also included. Although Carlson et al. recommended a
minimal LD parameter r2 threshold of 0.5 for the tagging
SNP selection [19], the 90 USA individuals in the EGP
database were a mixed ethnic population, and Asian pop-
ulations (including Chinese) have lower haplotype diver-
sity and thus higher pairwise LD compared with other
populations [20].
Therefore we thought the threshold (r2 = 0.4) in our study
might be adequately stringent according to a recent study
[17]. Among these 29 common SNPs, we selected five tag-
ging SNPs based on the calculation of pairwise LD: two
non-synonymous SNPs (rs2228000, 21151C  >  T  or
A499V and rs2228001, 33512A > C or K939Q), two com-
mon SNPs in the promoter region (rs2607775, 947C > G
and rs3731055, 603G  >  A), and one common SNP
(rs3729587, 12413C > G) at an exon-intron boundary.
XPC genotyping
Genomic DNA was extracted from the whole blood using
a DNA blood kit (Gentra Corp., Minnesota, USA) accord-
ing to the instructions of the manufacturer and stored at -
20°C until used. Genotyping was performed by the 5'-
nuclease (TaqMan) assay with fluorescent minor groove
binding probes [21] at Chinese National Human Genome
Center in Shanghai, China. The TaqMan primers and
probes were designed by using the Primer Express Oligo
Design software v2.0 (ABI PRISM) (available upon
request). PCR reactions were performed in 384-well
plates, each well containing 5 ng DNA, 2.5 μL 2 × TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster
City, CA), 0.083 μL 40 × Assay Mix. PCR reaction was ini-
tiated at 95°C for 10 min, followed by 20 cycles of 15 s at
92°C and 1 min at 60°C, followed by 30 cycles of 15 sec-
onds at 89°C and 1.5 min at 60°C. After PCR, the fluores-
cence was detected by the ABI PRISM 7900 HT Sequence
Detection System (Applied Biosystems). Two blank
(water) controls and two duplicated samples with known
genotypes in each 384-well plate were used for the assay
quality control. Each SNP that had fluorescence intensity
that met the criteria of three clear clusters in two scales
generated by the SDS software (ABI) was considered a suc-
cessful genotype call. As a result, genotype calls failed in
26 (2.6%) controls and 43 (4.2%) cases in the rs3731055
locus, 17 (1.7%) controls and 18 (1.8%) cases in the
rs2607775 locus, 78 (7.7%) controls and 74 (7.3%) cases
in the rs3729587 locus, 21 (2.1%) controls and 16 (1.6%)
cases in the rs2228000 locus and 19 (1.9%) controls and
19 (1.9%) cases in the rs2228000 locus owing to DNA
quantity or quality. For quality control, 5% of the samples
were re-tested and the concordance was 99.9%.
Statistical analysis
Differences between the cases and controls in selected
demographic variables, including smoking status, smok-
ing quantity (pack-years), andfamily history of cancer
were evaluated by the χ2test. The paired T-test was also
performe d to evaluate the difference in age and smoking
quantity (pack-years). The χ2test for trend was used to
evaluate the increasing levels of smoking (i.e., the trend of
never smokers, < 30 pack-years, and > 30 pack-years). The
Hardy-Weinberg equilibrium of the alleles at each indi-
vidual locus was assessed by a goodness-of -fit χ2 test, with
one degree of freedom to compare the observed genotypes
frequencies with the expected ones among the controls.
We also used χ2test to evaluate differences in genotypic
and allele frequencies. The linkage among SNPs in the
XPC gene was estimated by the LD coefficient (D') that
was calculated by the LDA program [22]. All genotype
data of each sample were taken to infer the haplotypes by
using the PHASE 2.0 program [23], a software for the
reconstruction of haplotypes from the observed genotype
data by using a Bayesian statistical approach. We also used
the THESIAS program, a software based on the maximum
likelihood model described by Tregouet et al. [24] and
linked with the Stochastic-EM algorithm [25], to estimate
the haplotype frequencies and compared the haplotypes
with those derived from the PHASE program [23]. The
associations between the frequencies of variants in the
XPC gene and lung cancer risk were estimated by comput-BMC Cancer 2007, 7:81 http://www.biomedcentral.com/1471-2407/7/81
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ing odds ratios (ORs) and 95% confidence intervals (CIs)
from the logistic regression models with adjustment for
age, sex, residential area, family history of cancer, and
pack-years of smoking. Potential gene-smoking interac-
tion at a multiplicative scale was also evaluated in the
logistic regression analysis and tested by comparing the
changes in deviance (-2 log likelihood) between the mod-
els for main effects with or without the interaction term.
All the statistical analyses were performed with Statistical
Analysis System software (v.8.0e; SAS Institute, Cary, NC).
Results
The primary information of the selected SNPs from differ-
ent database and the observed genotyping data is shown
in Table 1. Although the observed MAFs of all SNPs were
very similar between the cases and controls, the observed
MAFs of two non-synomynous SNPs (i.e., A499V and
K939Q) from the controls (0.32 and 0.36, respectively)
were close to that (0.30 and 0.38, respectively) for Chi-
nese obtained in the HapMap database but higher than
that (0.24 and 0.34, respectively) from the EGP database.
However, the observed MAFs of the other three SNPs, not
available in the HapMap database, were dramatically dif-
ferent from those obtained from the EGP database, sug-
gesting that indeed these SNPs may have some ethnic
differences in their MAFs. Thus, our original selection of
these SNPs from the mixed populations in the EGP data-
base was not optimal and may not represent the LD in
Chinese populations.
Epidemiologic data has been described elsewhere [17].
Briefly, the mean age of cases was 60.0 ± 10.8, which was
no significant difference with that in controls (59.7 ±
12.0, P = 0.61). However, the case group had a higher
prevalence of smoking (68.8%) than the controls (52.2%,
P < 0.001). Furthermore, the cases had higher values of
pack-years smoked than the controls (P for trend < 0.001);
44.5% of smokers among the cases smoked for ≥ 30 pack-
years, whereas this value was only 25.4% among the con-
trols (P < 0.0001). The cases were more likely than the
controls to report a family history of cancer in their first-
degree relatives (17.1% versus 12.8%; P  = 0.0059).
Among the cases, 430 (42.6%) were classified as adeno-
carcinoma (AC), 335 (33.2%) as squamous cell carci-
noma (SCC), 65 (6.4%) as small cell lung carcinoma
(SCLC) and 180 (17.8%) as other types, including large
cell, mixed cell or undifferentiated carcinomas.
Genotype frequencies of the five selected XPC  tagging
SNPs among cases and controls are shown in Table 2.
There was no significant difference between genotype dis-
tributions of the control subjects and that expected from
the Hardy-Weinberg equilibrium (data not shown).
Although the rs3731055 A  allele frequency was lower
among the cases than among the controls (25.1% vs.
27.5%), the difference was not statistically significant (P =
0.091), whereas the allele frequencies of other polymor-
phisms (i.e., rs2607775 G  allele, rs2228000 T  allele,
rs2228001 C allele, and rs3729587 G allele) werenon-sig-
nificantly higher among the cases than among the con-
trols. When lung cancer cases were stratified by tumor
histology, rs3731055 genotype distribution among the
lung AC was significantly different from that among the
controls (P = 0.024). Specifically, the rs3731055 A allele
frequency was lower in the lung AC group (22.9%) but
higher in the SCLC group (36.2%), compared to that of
the controls (27.5%; P = 0.012 and P = 0.035, respec-
tively) (Table 2).
The associations between the genotypes of XPC tagging
SNPs and lung cancer risk are also shown in Table 2, in
which all adjusted ORs and 95% CIs were calculated using
the common homozygous genotype as the reference
group, assuming a recessive genetic model as seen in XP
patients [26]. In the individual tagging SNP analysis, the
combined rs3731055 AG+AA  genotype was associated
with a significantly decreased risk of all lung cancer, com-
pared with the rs3731055 GG  genotype (adjusted OR,
0.82; 95% CI, 0.68 – 0.99; P = 0.036), but there was no
evidence of associations between the genotypes of other
tagging SNPs and overall lung cancer risk. When the
results were stratified by tumor histology, we found that
compared with the rs3731055 GG  genotype, the com-
bined rs3731055 AG+AA genotype was associated with a
significantly decrease risk of lung AC (adjusted OR, 0.71;
95% CI, 0.56 – 0.90; P = 0.004) but an increase risk of the
SCLC group (adjusted OR, 1.79; 95% CI, 1.05 – 3.07; P =
0.034).
The results of the haplotype analysis are shown in Table 3,
and there were a total of eleven estimated haplotypes out
of the 32 (i.e., 25) possible haplotypes in this study popu-
lation. Compared with the most common haplotype
GCCCC, haplotype ACCCA  was associated with a
decreased risk of lung AC (OR, 0.78; 95% CI, 0.62 – 0.97;
P = 0.026) but an increased risk of SCLC (OR, 1.68; 95%
CI, 1.04 – 2.71; P = 0.032), which is consistent with the
results for rs3731055 A allele that was present in haplo-
type ACCCA.
We further performed the stratification analysis for the
variant rs3731055 genotypes. As show in Table 4, we
found that the protective effect of rs3731055 AG+AA was
more pronounced in young subjects (≤ 60, adjust OR,
0.65; 95% CI, 0.50 – 0.85; P  = 0.001), non-smokers
(adjust OR, 0.74; 95% CI, 0.55 – 0.99; P = 0.044) and
patients with lung AC (adjusted OR, 0.71; 95% CI, 0.56 –
0.90; P = 0.004), whereas these genotypes remained a risk
factor for the SCLC group (adjusted OR, 1.79; 95% CI,
1.05 – 3.07; P = 0.034).BMC Cancer 2007, 7:81 http://www.biomedcentral.com/1471-2407/7/81
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Discussion
In this large-scale case-control study, we investigated the
associations between five tagging SNPs of the DNA repair
gene XPC and risk of lung cancer in a Chinese population.
Our results showed that the rs3731055 AG+AA genotype
was associated with a decreased overall risk of lung cancer,
especially among young subjects (age ≤ 60 years old),
non-smokers, and patients with lung AC, but an increased
risk of SCLC. When we evaluated the haplotypes derived
from all 5 tagging SNPs, we also found that the haplotype
ACCCA  containing the rs3731055 A  allele was signifi-
cantly associated with a decreased risk of lung AC but an
increased risk of SCLC. Considering both potential bio-
logical functions and use of the tagging SNPs representa-
tive of other untyped SNPs, our results may be due to the
rs3731055 SNP that is in LD with A499V and K939Q (r2
= 0.17 and 0.21, respectively, in this study population,
stronger than 0.025 and 0.040, respectively, obtained
from the mixed populations in the NIEHS SNP database),
or it is likely that the rs3731055 SNP may be in LD with
other untyped disease-causing SNPs. In addition, studies
showed that the XPC  promoter region contains some
binding sites of transcription factors, such as p53 [27],
AP1, and EGR1 [28]; thus, rs3731055 G > A change might
alter the effect on these protein-DNA interactions. How-
ever, the functional relevance of rs3731055 SNP needs
further investigations.
XPC is an important damage-recognition protein that rec-
ognizes a variety of bulky DNA damage, including UV-
induced photolesions and chemical carcinogen-induced
DNA adducts, that are repaired by both transcription-cou-
pled and global genome repair processes [29,30]. XPC can
also interact with many other important proteins, such as
the transcription factor IIH (i.e., TFIIH) [31,32] and the
centrisome protein Centrin 2 (CEN2) [33]. In addition to
its role in DNA repair, XPC also play an important role in
cell-cycle arrest and activation of the p53 pathway [34].
Furthermore, reduced XPC mRNA and protein levels were
more frequently observed in both XP heterozygotes [35]
and lung cancer patients [36], suggesting that the amount
of XPC may modulate susceptibility to cancer.
Table 3: Associations between frequencies of inferred XPC haplotypes and risk of lung cancer
Histologic types of lung cancer
XPC haplotypesa Controls Cases Adenocarcinomas Squamous cell Small cell
n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
All subjects 2022 2020 860 670 130
GCCCC 721 (35.6) 737 (36.5) 1.00 328 (38.1) 1.00 243 (36.3) 1.00 35 (26.9) 1.00
GCCTA 615 (30.5) 625 (30.9) 0.99 (0.85–1.16) 278 (32.3) 0.99 (0.82–1.21) 208 (31.0) 1.00 (0.81–1.24) 42 (32.3) 1.41 (0.89–2.23)
ACCCA 453 (22.7) 414 (20.5) 0.89 (0.76–1.06) 160 (18.6) 0.78 (0.62–0.97)* 153 (22.8) 1.00 (0.79–1.27) 37 (28.5) 1.68 (1.04–2.71)*
ACGCA 100 (4.6) 90 (4.4) 0.88 (0.65–1.19) 36 (4.2) 0.79 (0.53–1.18) 24 (3.6) 0.71 (0.45–1.14) 7 (5.4) 1.44 (0.62–3.33)
GGGCA 74 (3.7) 78 (3.9) 1.03 (0.74–1.44) 33 (3.8) 0.98 (0.64–1.51) 22 (3.3) 0.88 (0.54–1.45) 6 (4.6) 1.67 (0.68–4.10)
GCGCC 18 (0.9) 28 (1.4) 1.52 (0.83–2.78) 11 (1.3) 1.34 (0.63–2.88) 7 (1.0) 1.15 (0.48–2.80) 0 (0.0) ---
Others b 41 (2.0) 48 (2.4) 1.15 (0.75–1.76) 14 (1.6) 0.75 (0.40–1.40) 13 (1.9) 0.94 (0.50–1.78) 3 (2.3) 1.51 (0.44–5.11)
a Polymorphic bases were listed in the 5' to 3' order.
b Others including the haplotypes with frequencies of less than 1%.
*P < 0.05a
Table 1: Primary information of selected SNPs of the XPC gene
Gene [accession 
no.] and locus
NCBI rs no. location AAa change Base change MAFb of cases MAFb of controls MAFb in EGPc MAFb in HapMapd % genotyped
XPC [NCBI: 
AY131066] 3p25.1
rs3731055 000603, close 
to 5'UTR
G > A 0.25 0.27 0.07 --- 96.6
rs2607775 000947, close 
to 5'UTR
C > G 0.04 0.04 0.35 --- 98.3
rs3729587 012413, intron 
5
C > G 0.11 0.11 0.35 --- 92.5
rs2228000 021151, exon 
9
A499V C > T 0.33 0.32 0.24 0.30 98.2
rs2228001 033512, exon 
16
K939Q A > C 0.38 0.36 0.34 0.38 98.2
aAA: amino acid.
bMAF: Minor allele frequencies.
cEGP: US environmental Genome Project SNP database.
dHapMap: For Chinese included in the International HapMap Project.BMC Cancer 2007, 7:81 http://www.biomedcentral.com/1471-2407/7/81
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Although the XPC protein is known to play an important
role in the NER pathway, the results of published associa-
tion studies on XPC SNPs and risk of lung cancer remain
inconsistent. There are only a few published studies that
investigated the role of XPC SNPs in the etiology of lung
cancer, mostly in Asian populations. For example, Hu et
al. reported that compared with the 499CC  (i.e.,
rs2228000) and 939AA  (i.e., rs2228001) wild-type
homozygotes, subjects carrying 499CT+TT  and 939
AC+CC  respectively had a 1.57-fold and 1.21-fold
increased the risk of lung cancer in a Chinese population
[14], but this association was not observed in another
Chinese study [37]. More recently, Lee et al. found that
rs3731055AA  genotype was associated with a 2.1-fold
increased risk for lung SCC compared to the
rs3731055GG genotype in a Korean population of 432
lung cancer patients and 432 healthy controls[15]. These
differences in risk associations may be due to different eti-
ology and mechanisms of lung cancer in the study popu-
lations with different ethnic background. In a Spanish
population of 359 lung cancer patients and 375 healthy
controls, Marin et al. found that the frequency of XPC
PAT+ allele was 45.0% in cases and 39.5% in controls, the
difference being statistically significant (P = 0.032) [38].
Similarly, Vogel et al. [39] also reported that XPC
Lys939Gln, which is linked with XPC PAT, may be risk
factor for lung cancer in another Europe cohort study. In
order to verify the association, we also conducted this
large-scale study and did not find any significant associa-
tion on Lys939Gln (37.5% vs. 35.8%). This difference
may be due to the different ethnic background or small
sample size with limited statistical power.
Some recent studies had shown that mutations in the epi-
dermal growth factor receptor gene, which often took
place among the patients with lung AC, were more fre-
quent in never smokers and women in eastern popula-
tions, whereas such mutations were more frequent in
smokers and men in western populations [40,41]. These
observations suggested that the arising incidence of lung
AC may be associated with not only environmental risk
factors, such as N-nitrasomines or other carcinogens in
the air pollutions[42,43], but also genetic susceptibility
Table 2: Frequency distributions of XPC genotypes and their associations with risk of lung cancer
Histologic type Histologic type
XPC 
genotypes
Controls n (%) Cases n (%) Adenocarcinom
a n (%)
Squamous cell 
n (%)
Small cell 
n (%)
All Cases OR 
(95% C.I.)
Adenocarcinoma 
OR (95% CI)
Squamous cell 
OR (95% CI)
Small cell OR 
(95% CI)
rs3731055
GG 512 (52.0) 541 (55.9) 247 (60.0) 174 (54.5) 24 (38.7) 1.00 1.00 1.00 1.00
AG 404 (41.0) 366 (37.8) 141 (34.2) 126 (39.4) 31 (50.0) 0.83 (0.69–1.01) 0.71 (0.56–0.92)** 0.90 (0.68–1.20) 1.69 (0.97–2.96)
AA 69 (7.0) 60 (6.3) 24 (5.8)* 20 (6.2) 7 (11.3) 0.76 (0.52–1.11) 0.67 (0.41–1.10) 0.83 (0.47–1.45) 2.44 (0.99–6.02)
AG+AA 473 (48.0) 426 (44.1) 165 (40.0) 146 (45.5) 38 (61.3) 0.82 (0.68–0.99)* 0.71 (0.56–0.90)** 0.86 (0.66–1.13) 1.79 (1.05–3.07)*
A MAFa 27.5% 25.1% 22.9%* 25.9% 36.2%*
rs2607775
CC 925 (93.1) 913 (92.0) 390 (92.2) 306 (92.7) 58 (90.6) 1.00 1.00 1.00 1.00
CG 65 (6.5) 77 (7.8) 31 (7.3) 24 (7.3) 6 (9.4) 1.16 (0.82–1.66) 1.06 (0.67–1.67) 1.08 (0.64–1.81) 1.16 (0.47–2.88)
GG 4 (0.4) 2 (0.2) 2 (0.5) 0 (0.0) 0 (0.0) 0.78 (0.14–4.34) 1.60 (0.28–9.02) --- ---
CG+GG 69 (6.9) 79 (8.0) 33 (7.8) 24 (7.3) 6 (9.4) 1.15 (0.81–1.62) 1.10 (0.71–1.72) 1.08 (0.64–1.81) 1.16 (0.47–2.88)
G MAFa 3.7% 4.1% 4.1% 3.6% 4.7%
rs2228000
CC 446 (45.1) 452 (45.5) 184 (43.3) 149 (44.9) 31 (48.4) 1.00 1.00 1.00 1.00
CT 456 (46.1) 435 (43.8) 193 (45.4) 149 (44.9) 25 (39.1) 0.98 (0.81–1.19) 1.05 (0.82–1.35) 1.01 (0.77–1.34) 0.79 (0.46–1.38)
TT 88 (8.8) 107 (10.7) 48 (11.3) 34 (10.2) 8 (12.5) 1.28 (0.93–1.77) 1.42 (0.95–2.13) 1.20 (0.75–1.92) 1.37 (0.59–3.14)
CT+TT 544 (54.9) 542 (54.5) 241 (66.7) 183 (55.1) 33 (51.6) 1.03 (0.86–1.24) 1.11 (0.88–1.40) 1.04 (0.80–1.36) 0.88 (0.53–1.48)
T MAFa 31.9% 32.6% 34.0% 32.7% 32.0%
rs2228001
AA 404 (40.7) 390 (39.4) 163 (38.3) 129 (39.2) 30 (47.6) 1.00 1.00 1.00 1.00
AC 465 (46.9) 459 (46.3) 198 (46.5) 153 (46.5) 28 (44.4) 1.01 (0.83–1.22) 1.03 (0.80–1.33) 1.04 (0.78–1.38) 0.80 (0.47–1.38)
CC 123 (12.4) 142 (14.3) 65 (15.2) 47 (14.3) 5 (8.0) 1.17 (0.88–1.56) 1.31 (0.92–1.88) 1.14 (0.75–1.72) 0.53 (0.20–1.40)
AC+CC 588 (59.3) 601 (60.6) 263 (61.7) 200 (60.8) 33 (52.8) 1.04 (0.87–1.25) 1.09 (0.86–1.38) 1.06 (0.81–1.39) 0.74 (0.44–1.25)
C MAFa 35.8% 37.5% 38.5% 37.5% 30.1%
rs3729587
CC 768 (82.3) 756 (80.8) 329 (82.4) 260 (84.1) 47 (81.0) 1.00 1.00 1.00 1.00
CG 130 (14.0) 149 (15.9) 59 (14.8) 42 (13.3) 9 (15.5) 1.14 (0.88–1.48) 1.09 (0.77–1.53) 0.93 (0.62–1.38) 1.09 (0.52–2.32)
GG 35 (3.7) 31 (3.3) 12 (2.8) 8 (2.6) 2 (3.5) 0.90 (0.54–1.50) 0.82 (0.41–1.61) 0.59 (0.26–1.33) 0.86 (0.20–3.78)
CG+GG 165 (17.7) 180 (19.2) 71 (17.6) 50 (15.9) 11 (19.0) 1.09 (0.86–1.39) 1.03 (0.75–1.41) 0.85 (0.59–1.23) 1.04 (0.52–2.08)
G MAFa 10.7% 11.3% 10.4% 9.3% 11.2%
a MAF: minor allele frequency
*P < 0.05; **P < 0.01.BMC Cancer 2007, 7:81 http://www.biomedcentral.com/1471-2407/7/81
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factors in different ethnic groups and possible different
smoking behaviors.
A recent animal study had shown that 100% of XPC-defi-
cient mice develop spontaneous lung tumors, the major-
ity of which were adenomas; furthermore, when the mice
had XPC and Gadd45a deleted at the same time, their lung
adenomas were progressing to non-small cell lung adeno-
carcinomas [44]. These results suggested that genetic alter-
ations in XPC, in interaction with environmental factors,
could result in altered susceptibility to different histologi-
cal types of lung cancer, particularly in the presence of
other genetic susceptibility factors. Indeed, the finding
that rs3731055 AG+AA  genotype or haplotype ACCCA
were associated with an increased risk of SCLC in the
present study suggests that different histopathological
types may have different etiologies. Recently, Hollander et
al. reported that some allelic loss of XPC in the lung of
mice, coupled with carcinogens such as polycyclic aro-
matic hydrocarbons, resulted in highly frequent small cell
lung cancer and some non-small cell lung cancer [45].
However, the result on SCLC may be due to chance
because of the relatively small number of observations in
the subgroup of patients with SCLC.
In the present study, we found that the protective effect of
rs3731055AG+AA  genotype was more pronounced
among young people (≤ 60 years old), suggesting that
such a protective effect may have been diminished
because of prolong exposure, as age increased, to N-nitro-
somines or other carcinogens When the subjects were
divided into three subgroups according to cumulative cig-
arette consumption (i.e., 0 pack-years, < 30 pack-years,
and ≥ 30 pack-years of smoking), we observed that this
protective effect was more evident in the never smokers.
This result further suggests that cigarette smoking may not
be the major pathogenic agent involved in the initiation
of lung AC but that some as-yet-unidentified carcinogens
may have played a major role in the development of lung
AC in this study population. This is consistent with a pre-
vious study in which lung AC were more frequent in never
smokers than in ever smokers in eastern Asians[41]. How-
ever, it is also possi ble that these findings may be due to
chance because of the small sample size in the subgroup.
Although the present study was considerably larger than
previous studies, it was a hospital-based study that has
several limitations. First of all, the participation rate was
still relatively low for both cases (77.8%) and controls
(81.3%), and about seven percent of DNA samples failed
in the genotyping for each locus, which may have
increased the probability of selection bias. However, the
general demographics and tobacco-exposure information
of subjects included in the final analysis were similar with
those of people who were excluded, and all lung cancer
patients and controls were matched on age, sex, and resi-
dential area, which may have minimized the selection
bias and confounding factors. Second, because some DNA
samples failed in the genotyping, we used the Bayesian
statistical method to infer the most probable haplotypes,
Table 4: Stratification analyses for associations between rs3731055 genotypes and risk of lung cancer by selected variables
XPC rs3731055 genotype
Variables Case (n = 967) Control (n = 985) Adjusted OR (95% CI)
GG AG/AA GG AG/AA GG AG/AA
Total 541 (0.56) 426 (0.44) 512 (0.52) 473 (0.48) 1.00 0.82 (0.68–0.99)*
Age (years)
≤ 60 282 (0.59) 195 (0.41) 240 (0.49) 245 (0.51) 1.00 0.65 (0.50–0.85)**
> 60 259 (0.53) 231 (0.47) 272 (0.54) 228 (0.46) 1.00 1.03 (0.80–1.34)
Sex
Male 420 (0.56) 329 (0.44) 382 (0.52) 353 (0.48) 1.00 0.82 (0.66–1.01)
Female 121 (0.55) 97 (0.45) 130 (0.52) 120 (0.48) 1.00 0.86 (0.59–1.24)
Smoke status
None-smoker 178 (0.60) 119 (0.40) 251 (0.53) 221 (0.47) 1.00 0.74 (0.55–0.99)*
Smoker 363 (0.54) 307 (0.46) 261 (0.51) 252 (0.49) 1.00 0.90 (0.71–1.13)
< 30 pack-years 136 (0.56) 107 (0.44) 136 (0.52) 127 (0.48) 1.00 0.88 (0.61–1.25)
≥ 30 pack-years 227 (0.53) 200 (0.47) 125 (0.50) 125 (0.50) 1.00 0.91 (0.66–1.24)
Family history of cancer
No 435 (0.54) 363 (0.46) 442 (0.52) 416 (0.48) 1.00 0.84 (0.69–1.03)
Yes 106 (0.63) 63 (0.37) 70 (0.55) 57 (0.45) 1.00 0.71 (0.43–1.18)
a ORs were obtained from a logistic regression model with adjustment for age, sex, residential area, and family history of cancer, and smoking (pack/
yr).
*P < 0.05; **P < 0.01.BMC Cancer 2007, 7:81 http://www.biomedcentral.com/1471-2407/7/81
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which may have potential errors. However, the difference
in haplotype frequencies between the Stochastic-EM algo-
rithm and the Bayesian method were not significantly dif-
ferent in either cases or controls, increasing the reliability
of haplotype estimation. Finally, although we consider
both the relevance of biological functions and the repre-
sentativeness of other untyped SNPs in selecting tagging
SNPs of the XPC gene, this study may be limited because
of excluding some non-synonymous SNPs with low fre-
quencies, which may be more important in the etiology of
lung cancer.
Conclusion
In summary, this study provided further evidence that the
XPC genotypes and haplotypes may contribute to suscep-
tibility to lung cancer. Because the capture of the untyped
SNPs by the selected tagging SNPs was not optimal, some
causal SNPs may have been missed in this study. Further
larger studies with more comprehensively selected tagging
SNPs in Chinese populations are needed to confirm our
findings and some mechanistic studies are warranted to
investigate the functions of XPC SNPs and mechanisms
underlying their associations with lung cancer risk.
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